TBTC Study 33. An Evaluation of Adherence to Latent Tuberculosis Infection (LTBI) Treatment With 12 Doses of Once Weekly Rifapentine (RPT) and Isoniazid (INH) Given as Self-administered (SAT) Versus Directly-observed Therapy (DOT): iAdhere.

Trial Profile

TBTC Study 33. An Evaluation of Adherence to Latent Tuberculosis Infection (LTBI) Treatment With 12 Doses of Once Weekly Rifapentine (RPT) and Isoniazid (INH) Given as Self-administered (SAT) Versus Directly-observed Therapy (DOT): iAdhere.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Isoniazid (Primary) ; Rifapentine (Primary)
  • Indications Tuberculosis
  • Focus Therapeutic Use
  • Acronyms iAdhere
  • Most Recent Events

    • 18 May 2016 Results of post-hoc analysis of two phase III studies (PREVENT TB and iAdhere) presented at the 112th International Conference of the American Thoracic Society
    • 01 Dec 2012 Additional lead trial centre added as reported by European Clinical Trials Database record.
    • 01 Dec 2012 New source identified and integrated (European Clinical Trials Database record: EudraCT2012-002094-58).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top